Approval · Notice of Compliance 33425 · 2024
SITAGLIPTIN: Notice of Compliance 33425
Issued June 11, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33425
- Date
- June 11, 2024
- Company
- Sanis Health Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement Between Two Manufacturers
- Canadian reference product
- JANUVIA (Merck Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SITAGLIPTIN | 02548550 | Marketed |
| SITAGLIPTIN | 02548569 | Marketed |
| SITAGLIPTIN | 02548577 | Marketed |
Medicinal ingredients
- SITAGLIPTIN 25 MG per TAB
- SITAGLIPTIN 50 MG per TAB
- SITAGLIPTIN 100 MG per TAB